Faricimab for treatment of diabetic macular oedema

Published Date: 05th December 2022

Publication Authors: Kovacova A

Abstract
Diabetic macular oedema (DME) is a common cause of sight impairment in people with diabetes. Twenty-seven percent of people with type 1 diabetes develop DME within nine years of the disease onset. For people with type 2 diabetes, 25.4% of insulin dependent and 13.9% of those who do not use insulin have DME. Alarmingly, diabetes is estimated to increase by 56% in the United States by 2030, with DME causing visual impairment in up to 25% of patients.2 Given the current therapeutic options, there is a strong need for innovative drugs designed to reduce treatment burden by improved efficacy and durability.

 

Kovacova, A. (2022). Faricimab for treatment of diabetic macular oedema. Practical Diabetes. 39(6), pp.8-10. [Online]. Available at: https://doi.org/10.1002/pdi.2423 [Accessed 20 February 2023]

 

« Back